| Literature DB >> 30843374 |
Han-Gil Jeong1, Bong Geun Cha2, Dong-Wan Kang1,3,4, Do Yeon Kim1,3,4, Wookjin Yang1,3,4, Seul-Ki Ki1,3, Song I Kim1,3, Juhee Han1,3, Chi Kyung Kim5, Jaeyun Kim2,6, Seung-Hoon Lee1,3,4.
Abstract
Systemic inflammatory response syndrome (SIRS) is self-destructive and uncontrollable inflammatory response of the whole body triggered by infection, trauma, or a variety of severe injuries. Although reactive oxygen species play a pivotal role in the development of SIRS, the trials with conventional antioxidants have failed to improve patient outcome. Ceria nanoparticles (CeNPs) have potent, autocatalytic reactive oxygen species scavenging activities, which may have sufficient therapeutic effects for SIRS. Herein, 3 nm CeNPs are fabricated totally in aqueous phase by using 6-aminohexanoic acid (6-AHA) and their Ce3+ to Ce4+ ratio is increased to enhance antioxidative properties. The obtained 6-AHA-CeNPs demonstrate strong antioxidative and anti-inflammatory effects in various biofluids and inflammatory cells. In SIRS animal models, 6-AHA-CeNPs are demonstrated to reduce multiple organ injuries and inflammation. Moreover, 6-AHA-CeNPs decrease mortality and improve clinical scores of SIRS models. These findings suggest that 6-AHA-CeNPs have potential as a therapeutic nanomedicine for SIRS.Entities:
Keywords: 6-aminohexanoid acid; cerium oxide nanoparticles; nanotherapeutics; reactive oxygen species; systemic inflammatory response syndrome
Mesh:
Substances:
Year: 2019 PMID: 30843374 DOI: 10.1002/adhm.201801548
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933